AFC-HD AMS Life Science Co., Ltd. (2927) AI Stock Analysis

• Market Cap: ¥12.43B
• Dividend Yield: 3.5%
• Average Volume (3M): 19.54K
• Price to Earnings (P/E): 7.2
• Beta (1Y): 0.50
• Revenue Growth: 11.47%
• EPS Growth: 29.21%
• Country: JP
• Employees: 994
• Sector: Consumer Defensive
• Sector Strength: 51
• Industry: Packaged Foods
• EPS (TTM): 37.77
• Shares Outstanding: 14,387,699
• 10 Day Avg. Volume: 23,150
• 30 Day Avg. Volume: 19,536
• PEG Ratio: 0.90
• Price to Book (P/B): 0.85
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: ¥961.00 ▲(8.47%Upside)

JP:2927 scores well overall, driven by strong financial performance and attractive valuation. The company's income growth and profitability are impressive, though leverage and cash flow management need monitoring. Technical analysis suggests stability with slight upward momentum. These factors collectively make the stock a solid choice for investors looking for growth and value in the packaged foods industry.

AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model

Company Description

AFC-HD AMS Life Science Co., Ltd. (2927) is a Japanese company engaged in the development, manufacturing, and sale of health and beauty products. The company operates primarily in the life sciences sector, providing a wide range of products that include dietary supplements, skincare items, and other health-related goods. It focuses on leveraging advanced technology to deliver high-quality products that cater to the wellness and beauty needs of its customers. Through its commitment to innovation and quality, AFC-HD AMS Life Science Co., Ltd. aims to enhance the health and well-being of its consumers.

How the Company Makes Money

AFC-HD AMS Life Science Co., Ltd. generates revenue through the sale of its health and beauty products. The company's key revenue streams include direct sales to consumers through various retail channels, including online platforms and physical stores. Additionally, it may engage in wholesale distribution to other retailers and businesses, expanding its market reach. Strategic partnerships with other companies in the health and beauty industry can also contribute to its revenue, enabling the company to tap into new markets or enhance product offerings. By focusing on research and development, the company ensures a continuous pipeline of innovative products that meet consumer demands, further driving sales and profitability.

AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview

Summary

The company's financial health is robust, with strong growth in revenue and profitability reflected in the income statement. The balance sheet is stable yet shows moderate leverage, which necessitates careful management. Cash flow performance is mixed, with strong operating cash flow but negative free cash flow due to high capital investments. Overall, the company is on a positive growth trajectory, though attention to cash flow management is advised.

Income Statement

The company has demonstrated strong revenue growth, with a 18.0% increase over the past year, indicating robust demand for its products. Gross profit margin stands at 34.8%, showcasing effective cost control in production. Net profit margin improved to 4.1%, reflecting enhanced operational efficiency. The EBIT margin at 6.3% and EBITDA margin at 10.3% also suggest solid profitability. Overall, the income statement highlights a favorable growth trajectory with stable margins.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 1.64, which is manageable but indicates some leverage risk. Return on equity (ROE) is healthy at 9.0%, reflecting good returns for shareholders. The equity ratio of 29.6% suggests a balanced capital structure, though there is room for improvement in equity financing. The balance sheet is stable, with sufficient equity and controlled leverage.

Cash Flow

Operating cash flow to net income ratio is 1.23, indicating strong cash generation relative to profits. However, the free cash flow is negative, impacted by significant capital expenditures, which could pose liquidity concerns if sustained. Free cash flow to net income ratio is -1.49, suggesting challenges in translating profits into cash. While cash flow from operations is solid, high capital expenditure impacts overall cash health.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	30.19B	25.58B	23.00B	22.37B	15.82B
Gross Profit	10.49B	9.32B	8.58B	6.87B	4.55B
EBITDA	3.10B	2.59B	2.30B	2.86B	1.55B
Net Income	1.25B	1.10B	735.35M	1.50B	676.68M
Balance Sheet
Total Assets	47.03B	41.07B	37.35B	35.75B	18.55B
Cash, Cash Equivalents and Short-Term Investments	12.17B	11.18B	10.38B	9.22B	4.73B
Total Debt	22.89B	19.54B	17.13B	14.68B	3.95B
Total Liabilities	33.07B	27.91B	24.90B	23.09B	8.08B
Stockholders Equity	13.93B	13.11B	12.44B	11.92B	10.46B
Cash Flow
Free Cash Flow	-1.87B	-1.07B	534.45M	2.09B	917.75M
Operating Cash Flow	1.54B	865.28M	1.49B	2.58B	1.30B
Investing Cash Flow	-2.76B	-1.95B	-1.08B	-274.97M	-458.72M
Financing Cash Flow	2.23B	1.88B	1.16B	2.19B	-574.94M

AFC-HD AMS Life Science Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 886.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Positive. The current price of 886 is above the 20-day moving average (MA) of 879.60, above the 50-day MA of 867.32, and above the 200-day MA of 842.86, indicating a bullish trend. The MACD of 6.75 indicates Positive momentum. The RSI at 63.78 is Neutral, neither overbought nor oversold. The STOCH value of 36.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2927.

AFC-HD AMS Life Science Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2927	78 Outperform	¥12.43B	7.17		3.50%	11.47%	29.21%
2903	74 Outperform	¥17.90B	19.10		1.61%	5.15%	-15.30%
Sector *	65 Neutral	$24.37B	12.95	-0.84%	3.08%	1.71%	-10.31%
2597	64 Neutral	¥12.52B	23.16		0.86%	10.19%	38.34%
2935	62 Neutral	¥12.19B	11.95		2.66%	-1.44%	0.88%
2224	54 Neutral	¥10.95B	256.65		0.22%	-2.72%	1.41%
2818	52 Neutral	¥12.09B	207.68		1.38%	10.29%	-52.86%

AFC-HD AMS Life Science Co., Ltd. Corporate Events

AFC-HD AMS Life Science Reports Strong Quarterly Financial Results

AFC-HD AMS Life Science Co., Ltd. reported a significant increase in its quarterly financial results, with net sales rising by 10.7% and operating profit increasing by 23.9% compared to the previous year. The company’s strong financial performance reflects its robust market positioning and potential positive implications for stakeholders, as indicated by the 53.1% rise in profit attributable to owners of the parent.